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Primary systemic vasculitides (PSV) in children belong
to the most challenging conditions in paediatric rheu-
matology practice. The spectrum of vasculitis affecting
children as well as their clinical presentations differ
from that of adults. Apart from relatively common
Henoch-Shönlein purpura and Kawasaki disease, chronic
PSV are extremely rare in childhood. They include
mainly childhood polyarteritis nodosa (cPAN), Takayasu
arteritis (cTA) and granulomatosis with polyangiitis
(cGPA, formerly Wegener´s granulomatosis). From
organ-specific diseases, primary CNS angiitis (PACNS)
has been increasingly recognised in children over the
recent years. Differential diagnosis of vasculitis covers
wide spectrum of systemic diseases of inflammatory and
neoplastic origin as well as etiologically heterogeneous
group of non-inflammatory conditions reffered to as
“pseudovasculitis”. In general, diagnostic confirmation of
vasculitis requires histopathological or angiographic evi-
dence of vascular involvement. Main diagnostic and
treatment principles and classification criteria for the
main vasculitides will be reviewed.
Principles of vasculitis assessment have been formulated
by the OMERACT (Outcome Measures in Rheumatology)
Vasculitis Working Group.1 Reversible features of acute
morbidity directly related to the underlying inflammation
are captured by the disease activity domain while irreversi-
ble consequences of previous active disease or long-term
sequleae of treatment adverse effects form the basis of the
disease damage domain. Physical function in terms of the
degree of disability as well as psychosocial functioning
including educational and vocational aspects are additional
important components of patient-reported outcomes
covered by the domain of health-related quality of life
(HRQL). Paediatric-specific tools for vasculitis disease
activity and damage assessment have been derived from
adult instruments. Principles of Paediatric Vasculitis
Activity Score (PVAS) and Paediatric Vasculitis Damage
Index (PVDI) will be explained2,3.
Availability of childhood vasculitis classification and
disease assessment tools has enabled initiation of the first
paediatric vasculitis clinical trials. Ongoing international
activities in the field of vasculitis include prospective
disease registries that would allow update of disease classi-
fication and development of diagnostic criteria as well as
improvement and validation of disease assessment tools.
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